Omote A, Muramatsu M, Sugimoto Y, Hosono S, Murakami R, Tanaka H, Watanabe Y, Sano H, Kato K
Department of Internal Medicine, Kamo Hospital, Motoshiro-cho, Toyota.
Intern Med. 1997 Jul;36(7):508-13. doi: 10.2169/internalmedicine.36.508.
A 46-year-old female patient who was diagnosed with systemic sclerosis (SSc) developed rapidly progressive renal failure without elevation of blood pressure or plasma renin concentration. Renal biopsy revealed necrotizing crescentic glomerulonephritis (pauci-immune type) and the myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibodies (MPO-ANCA) titer was found to be elevated to 669 EU/ml. Methylprednisolone (MP) pulse therapy followed by prednisolone (PSL) and mizoribine (MZR) did not suppress the progression of renal failure. Therefore, we started double-filtration plasmapheresis (DFPP) which effectively removed MPO-ANCA and prevented renal failure despite the relatively low dose of immunosuppressive agents.
一名46岁被诊断为系统性硬化症(SSc)的女性患者出现快速进展性肾衰竭,血压和血浆肾素浓度未升高。肾活检显示为坏死性新月体性肾小球肾炎(少免疫型),且髓过氧化物酶特异性抗中性粒细胞胞浆自身抗体(MPO-ANCA)滴度升高至669 EU/ml。甲基泼尼松龙(MP)冲击治疗后联合泼尼松龙(PSL)和咪唑立宾(MZR)未能抑制肾衰竭进展。因此,我们开始进行双重滤过血浆置换(DFPP),尽管免疫抑制剂剂量相对较低,但该治疗有效清除了MPO-ANCA并预防了肾衰竭。